Compounded Pharmaceutical Regulation

Also known as: Pharmacy compounding regulation · Drug compounding oversight · Compounding pharmacy regulation · Regulation of compounding in the Philippines

Medicine

Definition

Compounded pharmaceutical regulation in the Philippines is the body of statutes, licensing rules, and health advisories governing the preparation of custom medicines by pharmacists — the mixing, assembling, and packaging of drugs to fit individual prescriptions that cannot be met by commercially manufactured products. The framework rests on two laws: Republic Act No. 9711 (the FDA Act of 2009), which strengthened the Food and Drug Administration’s (FDA) authority to license and regulate drug establishments and health products, and Republic Act No. 10918 (the Philippine Pharmacy Act of 2016), signed on 21 July 2016, which repealed the 1969 Pharmacy Law and provides that compounding and dispensing shall be done only by duly registered and licensed pharmacists in accordance with current good practice requirements. (LawPhil — RA 9711, LawPhil — RA 10918, SC e-Library — RA 10918)

Administratively, the FDA — an agency of the Department of Health — licenses pharmacies and drug establishments through the License to Operate (LTO) system, whose unified requirements cover establishments engaged in compounding, formulating, filling, packaging, and repackaging of health products, and the FDA issues public health warnings against unregistered drug products through its advisories system. Internationally, the Philippine regime parallels the distinction drawn in other jurisdictions between traditional patient-specific compounding and large-scale compounding that amounts to manufacturing — a line sharpened abroad after the 2012 New England Compounding Center fungal meningitis outbreak in the United States, which prompted the US Drug Quality and Security Act of 2013 and its categories of 503A pharmacies and 503B outsourcing facilities. (FDA — LTO guidelines page, FDA Philippines — Advisories, Wikipedia — Compounding)

Identities

Source Type	Identity
Wikipedia	Compounding (pharmaceutical compounding)
Wikidata	Q1303150 (Compounding)
DBpedia	http://dbpedia.org/resource/Compounding
ProductOntology	N/A
Wiktionary	N/A
Library of Congress Subject Headings (LCSH)	N/A
MeSH	Drug Compounding (D004339)
NCBI Taxonomy	N/A
AGROVOC	N/A
Google Scholar	pharmacy compounding regulation Philippines FDA RA 10918
ConceptNet	N/A
OpenCyc	N/A

Also Known As

Pharmacy compounding regulation
Drug compounding oversight
Compounding pharmacy regulation
Regulation of compounding in the Philippines

Examples and Analogies

Compounding versus manufacturing: the regulatory analog most often used is a spectrum, not a wall — a pharmacist preparing a single suspension for a patient who cannot swallow tablets is compounding, while a firm producing batches of copies of a commercially available drug is manufacturing and must meet full registration requirements; the US 503A/503B split after the NECC outbreak is the clearest foreign example of codifying that boundary. (Wikipedia — Compounding)
Licensed-person rule: under RA 10918 the compounding bench is reserved to licensed pharmacists, in the same way that only licensed physicians may prescribe — the license, not the workplace, defines who may lawfully prepare the medicine. (LawPhil — RA 10918)
GLP-1 example: amid global demand for weight-loss injectables, the Philippine College of Physicians has warned the public against compounded or non-FDA-registered versions of semaglutide and tirzepatide products (Ozempic, Mounjaro) sold online or through unverified clinics, an application of the registration-and-advisory system to modern compounded drugs. (Manila Bulletin — PCP warning on compounded GLP-1s)
Advisory system example: the FDA Philippines routinely publishes public health warnings against the purchase and use of unregistered drug products, the enforcement signal that flags compounded or imported preparations sold without authorization. (FDA Philippines — Advisories)

Usage Scenarios

1. Pharmacy Practice Compliance

Community and hospital pharmacists who prepare patient-specific formulations — suspensions for children, allergen-free alternatives, or shortages-driven preparations — must do so under RA 10918’s requirement that compounding be performed by registered and licensed pharmacists. (LawPhil — RA 10918)

2. Licensing of Drug Establishments

Pharmacies and other health-product establishments, including those engaged in compounding, obtain and maintain an FDA License to Operate under the unified licensing framework, which sets the requirements for personnel, premises, and documentation. (FDA — LTO guidelines page)

3. FDA Regulatory Enforcement

The FDA exercises its RA 9711 mandate over the manufacture, importation, distribution, and sale of drug products, acting against unregistered or adulterated preparations and issuing advisories that name products the public should not buy. (LawPhil — RA 9711, FDA Philippines — Advisories)

4. Managing Drug Shortages and Special Needs

Where a registered product is unavailable — a discontinued brand or a strength not marketed locally — compounding under professional supervision is the lawful channel for meeting the clinical need, which is why regulators distinguish it from copying commercially available drugs. (Wikipedia — Compounding)

5. Public Warnings on Novel Compounded Products

When new high-demand drugs appear — most prominently GLP-1 receptor agonists — professional societies and regulators issue warnings distinguishing registered products from compounded or counterfeit versions, guiding prescribers and patients. (Manila Bulletin — PCP warning on compounded GLP-1s, US FDA — concerns with unapproved GLP-1 drugs)

Strategies

Statutory reservation to professionals: RA 10918 anchors compounding authority in pharmacist licensure, creating a clear chain of professional accountability for each preparation. (LawPhil — RA 10918)
Licensing gatekeeping: the FDA’s LTO regime conditions market presence on demonstrated compliance of the establishment — including compounding areas — with regulatory requirements. (FDA — LTO guidelines page)
Registration as the default: RA 9711’s product registration and establishment licensing regime makes unregistered compounded or imported drugs presumptively unlawful to sell, inverting the burden onto sellers. (LawPhil — RA 9711)
Advisory-based risk communication: rather than relying solely on enforcement raids, the FDA publishes advisories on unregistered products, and medical societies amplify the warnings — as with compounded GLP-1 products. (FDA Philippines — Advisories, Manila Bulletin — PCP warning on compounded GLP-1s)
International benchmarking: Philippine practice references international experience — the US NECC outbreak and the DQSA response — in defining the frontier between compounding and manufacturing. (Wikipedia — Compounding, US FDA — concerns with unapproved GLP-1 drugs)

Security and Safety Measures

Licensed pharmacists only: the explicit statutory rule that compounding and dispensing be performed only by duly registered and licensed pharmacists, following good practice requirements. (LawPhil — RA 10918, SC e-Library — RA 10918)
Establishment licensing: FDA licenses to operate, covering compounding establishments, subject them to inspection and conformity requirements before they may lawfully function. (FDA — LTO guidelines page)
Public health advisories: the FDA’s advisories against unregistered drug products give consumers and pharmacists a running list of preparations flagged as unsafe or unlawful. (FDA Philippines — Advisories)
Professional society vigilance: organizations such as the Philippine College of Physicians issue public health advisories against compounded or unregistered versions of medicines in high demand, supplementing state capacity. (Manila Bulletin — PCP warning on compounded GLP-1s)
International surveillance: foreign regulator findings — such as US FDA warnings on illegally marketed compounded semaglutide and dosing errors with compounded products — inform domestic risk assessment of parallel products. (US FDA — concerns with unapproved GLP-1 drugs)

Historical Context

Before 2009, pharmacy and drug regulation rested on older statutes — the 1969 Pharmacy Law (RA 5921) and the food-drug-cosmetic framework administered by the Bureau of Food and Drugs. RA 9711 (FDA Act of 2009) renamed and strengthened the regulator as the Food and Drug Administration of the Philippines, broadening its licensing, registration, inspection, and enforcement powers over drug establishments and products. The Philippine Pharmacy Act of 2016 (RA 10918), signed on 21 July 2016, modernized the profession’s statute — repealing RA 5921 — and expressly reserved compounding and dispensing to licensed pharmacists operating under good practice requirements. (LawPhil — RA 9711, LawPhil — RA 10918, SC e-Library — RA 10918)

The modern tension in compounding regulation has been driven by global events and by market demand. In the United States, the 2012 New England Compounding Center fungal meningitis outbreak — roughly 750 illnesses and 63 deaths tied to compounded steroid injections — led to the Drug Quality and Security Act of 2013 and a sharper federal-state division between traditional compounding (503A) and outsourcing facilities (503B). In the Philippines, the same boundary questions surfaced with the surge in demand for GLP-1 weight-loss and diabetes injectables after 2023, when compounded semaglutide and tirzepatide products spread through online channels; the Philippine College of Physicians warned the public against compounded and non-FDA-registered versions of these drugs, and US FDA warnings about compounded GLP-1 products supplied international context. (Wikipedia — Compounding, Manila Bulletin — PCP warning on compounded GLP-1s, US FDA — concerns with unapproved GLP-1 drugs)

Challenges and Controversies

Compounded GLP-1 Products

The most visible current controversy concerns compounded semaglutide and tirzepatide: with registered brands in shortage and high prices in some markets, compounders have marketed versions that Philippine professional societies warn are not evaluated by the FDA and may be counterfeit, mislabeled, or sold without prescriptions — warnings echoed by the US FDA’s reports of dosing errors and adverse events with compounded GLP-1 drugs. (Manila Bulletin — PCP warning on compounded GLP-1s, US FDA — concerns with unapproved GLP-1 drugs)

The Compounding–Manufacturing Boundary

Regulators must distinguish patient-specific preparation from de facto small-scale manufacturing — a distinction tested historically by the NECC outbreak abroad and domestically by online sellers marketing compounded copies of commercially available drugs, which falls outside the lawful rationale for compounding. (Wikipedia — Compounding)

Online Sales and Unverified Channels

The growth of e-commerce and social-media sales of medicines — including compounded and unregistered products — strains a licensing system built around physical establishments, leaving advisories and consumer warnings as the rapid-response layer of the regime. (FDA Philippines — Advisories, Manila Bulletin — PCP warning on compounded GLP-1s)

Enforcement Capacity

As a licensing-based system, enforcement depends on FDA inspection and post-market surveillance resources; the persistence of unregistered drug products in the market — evidenced by the continuous stream of FDA public health warnings — indicates the gap between rules on paper and market practice. (FDA Philippines — Advisories, LawPhil — RA 9711)